Related Experiment Video

Updated: May 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Update in the management of chronic hepatitis B

Shannan R Tujios1, William M Lee

  • 1Division of Digestive and Liver Disease, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8887, USA. Shannan.Tujios@UTSouthwestern.edu

Current Opinion in Gastroenterology
|March 23, 2013
PubMed

Insights

Recent advancements in chronic hepatitis B (CHB) management include updated guidelines and potent first-line therapies. While current treatments suppress the virus, achieving a cure for hepatitis B requires novel approaches targeting viral replication and the immune system.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) affects millions globally, necessitating updated management strategies.
  • Understanding the natural history and risk factors for CHB progression is crucial for effective treatment.
  • Advances in antiviral therapies offer improved viral suppression and reduced disease complications.

Purpose of the Study:

  • To review recent developments in the management of chronic hepatitis B (CHB).
  • To synthesize findings from articles published between January 2012 and January 2013.

Main Methods:

  • Literature review of articles published between January 2012 and January 2013.
  • Analysis of updated international guidelines for CHB management.
  • Evaluation of recent discoveries in CHB natural history and treatment efficacy.

Main Results:

  • Updated guidelines incorporate new knowledge on CHB natural history and treatment indications.
  • Potent antiviral medications with high genetic barriers are recommended as first-line therapy.
  • Interferon response may be influenced by IL28B genotype and HBsAg/HBV DNA monitoring.
  • Entecavir and tenofovir achieve long-term viral suppression, reducing hepatocellular carcinoma and mortality.

Conclusions:

  • Current therapies suppress, but rarely eradicate, hepatitis B virus (HBV).
  • Drug resistance remains a significant challenge, particularly in resource-limited settings and previously treated patients.
  • Quantitative hepatitis B surface antigen (HBsAg) may aid personalized treatment decisions.
  • Novel therapies targeting HBV replication and the immune system are needed for CHB cure.
Abstract

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: